+

WO1998032862A3 - L-alanine deshydrogenase de mycobacterium marinum - Google Patents

L-alanine deshydrogenase de mycobacterium marinum Download PDF

Info

Publication number
WO1998032862A3
WO1998032862A3 PCT/EP1998/000484 EP9800484W WO9832862A3 WO 1998032862 A3 WO1998032862 A3 WO 1998032862A3 EP 9800484 W EP9800484 W EP 9800484W WO 9832862 A3 WO9832862 A3 WO 9832862A3
Authority
WO
WIPO (PCT)
Prior art keywords
hbt
tuberculosis
protein
alanine dehydrogenase
vaccine
Prior art date
Application number
PCT/EP1998/000484
Other languages
German (de)
English (en)
Other versions
WO1998032862A9 (fr
WO1998032862A2 (fr
Inventor
Leopold Flohe
Mahavir Singh
Bernd Hutter
Arend Kolk
Original Assignee
Leopold Flohe
Mahavir Singh
Bernd Hutter
Arend Kolk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leopold Flohe, Mahavir Singh, Bernd Hutter, Arend Kolk filed Critical Leopold Flohe
Priority to AU60979/98A priority Critical patent/AU6097998A/en
Publication of WO1998032862A2 publication Critical patent/WO1998032862A2/fr
Publication of WO1998032862A3 publication Critical patent/WO1998032862A3/fr
Publication of WO1998032862A9 publication Critical patent/WO1998032862A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0014—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
    • C12N9/0016—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4) with NAD or NADP as acceptor (1.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La tuberculose est une maladie infectieuse qui tue plus de 3 millions de personnes par an. Il existe un vaccin et différents procédés de diganostic et de thérapie mais vu le nombre croissant de victimes, l'efficacité de toutes ces mesures nécessite une amélioration urgente. La recherche se concentre sur la caractérisation d'antigènes qui sont sécrétés de façon précoce lors d'une infection puisque ces antigènes établissent le premier contact du système immunitaire avec l'agent infectieux. L'antigène de 40 kD dont il est question dans ce document se présente in vivo sous forme d'hexamère et, malgré un poids moléculaire élevé et l'absence d'une séquence-signal, on le trouve de façon extracellulaire déjà après quelques jours de croissance. Il constitue fonctionnellement une L-alanine déshydrogénase et réagit avec l'anticorps HBT-10 monoclonal dirigé contre cette protéine. HBT-10 fut le premier anticorps connu spécifique de la protéine de M. tuberculosis, qui ne produise pas de réaction croisée avec la souche vaccinale M. bovis BCG.
PCT/EP1998/000484 1997-01-29 1998-01-29 L-alanine deshydrogenase de mycobacterium marinum WO1998032862A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU60979/98A AU6097998A (en) 1997-01-29 1998-01-29 L-alanine dehydrogenase of mycobacterium marinum

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97101339.6 1997-01-29
EP97101339 1997-01-29

Publications (3)

Publication Number Publication Date
WO1998032862A2 WO1998032862A2 (fr) 1998-07-30
WO1998032862A3 true WO1998032862A3 (fr) 1998-11-12
WO1998032862A9 WO1998032862A9 (fr) 1998-12-23

Family

ID=8226418

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/000484 WO1998032862A2 (fr) 1997-01-29 1998-01-29 L-alanine deshydrogenase de mycobacterium marinum

Country Status (2)

Country Link
AU (1) AU6097998A (fr)
WO (1) WO1998032862A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU744325B2 (en) * 1997-01-29 2002-02-21 Lionex Gmbh Test kit for tuberculosis diagnosis or the like
US6316205B1 (en) 2000-01-28 2001-11-13 Genelabs Diagnostics Pte Ltd. Assay devices and methods of analyte detection
JP4233458B2 (ja) * 2002-04-16 2009-03-04 リウ、ジュン アラニンデヒドロゲナーゼ、セリンデヒドラターゼおよび／またはグルタミンシンテターゼを発現する結核ワクチンとしてのリコンビナントｂｃｇ株

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995017511A2 (fr) * 1993-12-23 1995-06-29 Agresearch New Zealand Pastoral Agriculture Research Institute, Ltd. Facteurs de virulence de mycobacteries et procede pour leur identification

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995017511A2 (fr) * 1993-12-23 1995-06-29 Agresearch New Zealand Pastoral Agriculture Research Institute, Ltd. Facteurs de virulence de mycobacteries et procede pour leur identification

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANDERSEN, Å.B. ET AL.: "Structure and function of a 40,000-molecular weight protein antigen of mycobacterium tuberculosis", INFECTION AND IMMUNITY, vol. 60, no. 6, June 1992 (1992-06-01), pages 2317 - 2323, XP002071002 *
KALTWASSER, G. ET AL.: "Enzymatic DNA amplification (PCR) in the diagnosis of extrapulmonary Mycobacterium tuberculosis infection.", MOLECULAR AND CELLULAR PROBES, vol. 7, 1993, pages 465 - 470, XP002071003 *

Also Published As

Publication number Publication date
AU6097998A (en) 1998-08-18
WO1998032862A2 (fr) 1998-07-30

Similar Documents

Publication Publication Date Title
WO1998008542A3 (fr) Composes et procedes destines au traitement et au diagnostic d'infections mycobacteriennes
CA2293489A1 (fr) Inhibiteurs de l'activite de sequences immunostimulatrices de l'adn
DK0950068T3 (da) Kollagen-bindende proteinsammensatninger og fremgangsmade til anvendelse
DE69723434D1 (de) Verfahren zur selektion und produktion von t-zell-peptide epitope und vakzine mit diese epitope
WO1995009232A3 (fr) Peptides representant des sites epitopes pour les agents induisant la meningite purulente et virale, et leur conducteur du systeme nerveux central, anticorps diriges contre ces derniers, et utilisations
AR020102A1 (es) Compuesto para la prevencion y/o tratamiento de la alergia; composicion farmaceutica, composicion cosmetica, composicion en forma de bebida, alimento y/oalimento para animales domesticos que lo comprende y uso de dicho compuesto o dicha composicion farmaceutica para la fabricacion de un alimento
NZ301290A (en) Mycobacterial proteins, micro-organisms producing same and vaccines thereof
DK0969873T3 (da) Multiple carbonhydratholdige glycopeptid-antigener, vaccine indeholdende dem og anvendelse deraf
Rolph et al. CD40 signaling converts a minimally immunogenic antigen into a potent vaccine against the intracellular pathogen Listeria monocytogenes
WO1996021734A3 (fr) Antigenes p15 et tyrosinase du melanome et leur utilisation dans des procedes diagnostiques et therapeutiques
AU7520398A (en) Test kit for tuberculosis diagnosis or the like
GB2355983A (en) Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class 1 molecule and an attaching means
WO2023172741A3 (fr) Vaccin contre le staphylococcus aureus utilisant un système de présentation d'antigènes multiples (maps) comprenant des antigènes de lymphocytes b et t, composition immunogène et leurs utilisations
WO2002054073A3 (fr) Modele de tuberculose humaine latente, antigenes diagnostiques et methodes d'utilisation associees
HK1081437A1 (en) Use of mycobacterial antigen mpb64 in the manufacture of a product for topical detection of active tuberculosis
WO2002034287A3 (fr) Nouvelles formulations de vaccin therapeutique
WO1998032862A3 (fr) L-alanine deshydrogenase de mycobacterium marinum
WO1996018646A3 (fr) Peptides de proteines de choc thermique et procedes de modulation d'une maladie auto-immune du systeme nerveux central
WO1998039027A3 (fr) Antigenes de sialyl lewis uilises comme cibles en immunotherapie
FR2265402A1 (en) Tuberculin active proteins and peptides prepn - from tubercle bacillus
FR2244539A1 (en) Tuberculin active proteins and peptides prepn - from tubercle bacillus
Løkensgard et al. Heat shock response in Actinobacillus actinomycetemcomitans
Ottenhoff et al. Antigen reactivity and autoreactivity: two sides of the cellular immune response induced by mycobacteria
WO2001040472A3 (fr) Antigènes dérivés de streptococcus pneumoniae
PT811067E (pt) Peptidos do virus da arterite equina anticorpos e sua utilizacao num teste de diagnostico

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD GH

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI

COP Corrected version of pamphlet

Free format text: PAGE 1, DESCRIPTION, REPLACED BY A NEW PAGE 1

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998531617

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载